Stock Taper
| DATE | TYPE | RATIO |
|---|---|---|
| 2025-10-31 | Reverse | 1:10 |
| 2024-09-27 | Reverse | 1:40 |
NewcelX Ltd., a biotechnology company, engages in developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company was founded in 2008 and is headquartered in Zurich, Switzerland.

IsletRx, NewcelX's lead clinical program, is a cell therapy in development for Type 1 Diabetes that aims to restore insulin production by transplanting stem cell-derived islet cells.
Overall rating: A
| PEER | PRICE | |
|---|---|---|
PRE | $25.76 | COMPARE |
SABS | $3.79 | COMPARE |
SRZN | $22.42 | COMPARE |
CELU | $1.58 | COMPARE |
KTTA | $0.56 | COMPARE |
GTBP | $0.63 | COMPARE |
NKGN | $0.04 | COMPARE |
MLEC | $0.36 | COMPARE |